RecruitingNCT06118723
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Studying Glioblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jasper Gerritsen
- Principal Investigator
- Jasper Gerritsen, MD PhDErasmus Medical Center
- Intervention
- Supramaximal resection(procedure)
- Enrollment
- 784 enrolled
- Eligibility
- 18-90 years · All sexes
- Timeline
- 2022 – 2028
Study locations (8)
- University of California, San Francisco (UCSF), San Francisco, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University Hospitals Leuven, Leuven, Belgium
- Universitätsklinikum Heidelberg, Heidelberg, Baden-Wurttemberg, Germany
- Technical University Munich, Munich, Bavaria, Germany
- Erasmus Medical Center, Rotterdam, South Holland, Netherlands
- Haaglanden Medical Centre, The Hague, South Holland, Netherlands
- Inselspital Universitätsspital Bern, Bern, Switzerland
Collaborators
Haaglanden Medical Centre · Universitaire Ziekenhuizen KU Leuven · University Hospital Heidelberg · Technical University of Munich · Insel Gruppe AG, University Hospital Bern · Massachusetts General Hospital · University of California, San Francisco
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06118723 on ClinicalTrials.govOther trials for Glioblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07326566Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIIIBlack Diamond Therapeutics, Inc.
- RECRUITINGPHASE1, PHASE2NCT07501559A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)Jecho Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT07464925A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade GliomaTetragon Biosciences Ltd
- RECRUITINGNCT07411690Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial TumorsMedical University of Warsaw
- RECRUITINGPHASE1NCT07480941Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaBeijing Biotech
- RECRUITINGPHASE2NCT07225621Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed GlioblastomaAlpheus Medical, Inc.
- RECRUITINGPHASE1, PHASE2NCT073912155G-PEARL: Paxalisib in Malignant Brain TumoursInstitute of Cancer Research, United Kingdom
- RECRUITINGNANCT07426848OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour PatientsRoyal College of Surgeons, Ireland